Improving the functional detection of sarcopenic obesity: prevalence and handgrip scoring in the OBESAR cohort
- PMID: 39467062
- DOI: 10.1002/oby.24157
Improving the functional detection of sarcopenic obesity: prevalence and handgrip scoring in the OBESAR cohort
Abstract
Objective: The study objectives were: 1) to detect early signs of low muscle function and assess sarcopenic obesity (SO) prevalence in patients with obesity; and 2) to introduce a new online diagnostic tool for scoring handgrip strength (HGS), adjusted for age and sex.
Methods: Patients from the OBESAR cohort (184 men and 499 women) were tested for body composition and functional testing (chair stand test or HGS based on the cutoffs from the European Society for Clinical Nutrition and Metabolism [ESPEN]/European Association for the Study of Obesity [EASO] or adjusted HGS [adHGS] based on reference values), and SO prevalence was calculated accordingly.
Results: Among the 683 patients (mean [SD], age 42.6 [12.8] years; BMI 44.4 [6.3] kg/m2), HGS averaged 25.6 (6.8) kg for women and 43.2 (10.4) kg for men. A total of 25.2% of patients had adHGS lower than the 10th percentile, but this was true for only 5.6% using ESPEN/EASO cutoffs of HGS. SO prevalence rates were different according to functional tests: 5.4%, 24.5%, and 3.2% for HGS, adHGS, and the chair stand test, respectively.
Conclusions: Using adHGS through a scoring process considering age and sex may help to detect early signs of SO in a primary care setting in order to better prevent SO through a personalized approach in adults with obesity. A free online application, "GRip And Sarcopenia Prediction" (GRASP), is proposed to diagnose probable SO.
© 2024 The Obesity Society.
References
REFERENCES
-
- NCD Risk Factor Collaboration (NCD‐RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population‐representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027‐1050.
-
- Meex RCR, Blaak EE, van Loon LJC. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev. 2019;20:1205‐1217.
-
- Li C‐W, Yu K, Shyh‐Chang N, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle. 2022;13:781‐794.
-
- Goodpaster BH, Bergman BC, Brennan AM, Sparks LM. Intermuscular adipose tissue in metabolic disease. Nat Rev Endocrinol. 2023;19:285‐298.
-
- Guillet C, Delcourt I, Rance M, et al. Changes in basal and insulin and amino acid response of whole body and skeletal muscle proteins in obese men. J Clin Endocrinol Metab. 2009;94:3044‐3050.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
